This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

66/100

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Background Development of new therapies for Alzheimer's disease (AD) is increasingly focused on more mildly affected populations, and requires new assessment and outcome strategies. Patients in early stages of AD have mild cognitive decline and no, or limited, functional impairment. To respond to these assessment challenges, we developed a measurement approach based on established scale items that exhibited change in previous amnestic Mild Cognitive Impairment (aMCI) trials. Methods Partial least squares regression with a longitudinal clinical decline model identified items from commonly used clinical scales with the highest combined sensitivity to change over time in aMCI and weighted these items according to their relative contribution to detecting clinical progression in patients' early stages of AD. The resultant AD Composite Score (ADCOMS) was assessed for its ability to detect treatment effect in aMCI/prodromal AD (pAD) clinical trial populations. Results ADCOMS consists of 4 Alzheimer's Disease Assessment Scale-cognitive subscale items, 2 Mini-Mental State Examination items, and all 6 Clinical Dementia Rating-Sum of Boxes items. ADCOMS demonstrated improved sensitivity to clinical decline over individual scales in pAD, aMCI and in mild AD dementia. ADCOMS also detected treatment effects associated with the use of cholinesterase inhibitors in these populations. Improved sensitivity predicts smaller sample size requirements when ADCOMS is used in early AD trials. Conclusions ADCOMS is proposed as new standard outcome for pAD and mild AD dementia trials, and is progressing in a CAMD-sponsored qualification process for use in registration trials of pAD.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Wang, J., Logovinsky, V., Hendrix, S. B., Stanworth, S. H., Perdomo, C., Xu, L., et al. (2016). ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. Journal of neurology, neurosurgery, and psychiatry. https://doi.org/10.1136/jnnp-2015-312383

Vancouver

Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. Journal of neurology, neurosurgery, and psychiatry. 2016. doi:10.1136/jnnp-2015-312383. PMID: 27010616.

BibTeX

@article{wang2016-27010616,
  author  = {Wang, J. and Logovinsky, V. and Hendrix, S. B. and Stanworth, S. H. and Perdomo, C. and Xu, L. and Dhadda, S. and Do, I. and others},
  title   = {{ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials}},
  journal = {Journal of neurology, neurosurgery, and psychiatry},
  year    = {2016},
  doi     = {10.1136/jnnp-2015-312383},
  pmid    = {27010616},
  url     = {https://doi.org/10.1136/jnnp-2015-312383}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Results ADCOMS consists of 4 Alzheimer's Disease Assessment Scale-cognitive subscale items, 2 Mini-Mental State Examination items, and all 6 Clinical Dementia Rating-Sum of Boxes items.
ADCOMS demonstrated improved sensitivity to clinical decline over individual scales in pAD, aMCI and in mild AD dementia.
ADCOMS also detected treatment effects associated with the use of cholinesterase inhibitors in these populations.

Why it matters

This study developed a composite clinical outcome score, ADCOMS, from items of established scales, which showed improved sensitivity to clinical decline in prodromal Alzheimer's disease, amnestic mild cognitive impairment, and mild Alzheimer's disease dementia. ADCOMS also detected treatment effects associated with cholinesterase inhibitors, but it is a measurement tool rather than a treatment itself.

Study details

Study designlongitudinal study
Evidence strengthModerate

How this study scored 66/100

Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for sample size and effect reported because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of neurology, neurosurgery, and psychiatry)
Journal's citation record	3 / 4	Journal of Neurology Neurosurgery & Psychiatry: journal h-index 336 (OpenAlex, 2026-10-29)
Study design	11 / 12	A randomised controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2016 — within 20 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (pubmed indexes it as a clinical or observational study)
Randomised / blinded	1 / 2	Randomised (as stated in the record)
Times cited	5 / 7	Cited 162 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	13.5 citations a year over 12 year(s) since 2016
Impact for its field and year	4 / 6	Cited 10.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	3 / 6	Cited by 16 other studies in this library
Still being cited	2 / 4	Cited 48 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Andrew Satlin: h-index 50 (OpenAlex, whole career)
Institution's track record	1 / 3	Cleveland Clinic: institution h-index 1,139 (OpenAlex)
Multi-centre collaboration	2 / 3	PubMed indexes it as a multicentre study
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 27010616)
Free to read	2 / 2	Free to read
Total	66 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

16 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Mild cognitive impairment

Also tagged “placebo-controlled”

783 studies in the library carry the topic tag “placebo-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →